Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment

Poitiers University Hospital1 site in 1 country35 target enrollmentOctober 2011

ConditionsDiabetic Macular Edema

Interventionsranibizumab

Drugsranibizumab

Overview

Phase: Phase 2
Intervention: ranibizumab
Conditions: Diabetic Macular Edema
Sponsor: Poitiers University Hospital
Enrollment: 35
Locations: 1
Primary Endpoint: Number of intravitreal injections of ranibizumab
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

In the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4. During follow-up a ranibizumab injection will be performed every 2 months in case of best-corrected visual acuity decreased more than 5 letters.

Registry

clinicaltrials.gov

Start Date

October 2011

End Date

July 2014

Last Updated

10 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Poitiers University Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•diabetes mellitus (1 or2)
•decreased vision from Diabetic Macular Edema (study eye Best Corrected Visual Acuity\<69 letters using E.T.D.R.S testing)
•macular edema